These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
234 related articles for article (PubMed ID: 30095787)
1. Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer. Fleming ND; Nick AM; Coleman RL; Westin SN; Ramirez PT; Soliman PT; Fellman B; Meyer LA; Schmeler KM; Lu KH; Sood AK Obstet Gynecol; 2018 Sep; 132(3):545-554. PubMed ID: 30095787 [TBL] [Abstract][Full Text] [Related]
2. Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer. Hansen JM; Sood AK; Coleman RL; Westin SN; Soliman PT; Ramirez PT; Fellman BM; Schmeler KM; Fleming ND Gynecol Oncol; 2018 Dec; 151(3):428-432. PubMed ID: 30366647 [TBL] [Abstract][Full Text] [Related]
3. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer. Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245 [TBL] [Abstract][Full Text] [Related]
4. A triage strategy in advanced ovarian cancer management based on multiple predictive models for R0 resection: a prospective cohort study. Feng Z; Wen H; Jiang Z; Liu S; Ju X; Chen X; Xia L; Xu J; Bi R; Wu X J Gynecol Oncol; 2018 Sep; 29(5):e65. PubMed ID: 30022629 [TBL] [Abstract][Full Text] [Related]
5. Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer. Fleming ND; Westin SN; Rauh-Hain JA; Soliman PT; Fellman BM; Coleman RL; Meyer LA; Shafer A; Cobb LP; Jazaeri A; Lu KH; Sood AK Gynecol Oncol; 2021 Jul; 162(1):65-71. PubMed ID: 33838925 [TBL] [Abstract][Full Text] [Related]
6. Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer. Fleming ND; Westin SN; Meyer LA; Shafer A; Rauh-Hain JA; Onstad M; Cobb L; Bevers M; Fellman BM; Burzawa J; Bhosale P; Zand B; Jazaeri A; Levenback C; Coleman RL; Soliman PT; Sood AK Int J Gynecol Cancer; 2021 Jan; 31(1):92-97. PubMed ID: 33154095 [TBL] [Abstract][Full Text] [Related]
7. CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy. Bregar A; Mojtahed A; Kilcoyne A; Kurra V; Melamed A; Growdon W; Alejandro Rauh-Hain J; Del Carmen M; Lee SI Gynecol Oncol; 2019 Mar; 152(3):568-573. PubMed ID: 30642626 [TBL] [Abstract][Full Text] [Related]
8. Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial-NCT02324595): a feasibility study. Gueli Alletti S; Bottoni C; Fanfani F; Gallotta V; Chiantera V; Costantini B; Cosentino F; Ercoli A; Scambia G; Fagotti A Am J Obstet Gynecol; 2016 Apr; 214(4):503.e1-503.e6. PubMed ID: 26529370 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Chemotherapy Increases R0 Cytoreduction Rate But Does Not Improve Final Outcome in Advanced Epithelial Ovarian Cancer. Medina-Franco H; Cortés-González R; Lambreton-Hinojosa F; Fimbres-Morales A; Vargas-Siordia JC Ann Surg Oncol; 2017 May; 24(5):1330-1335. PubMed ID: 27995454 [TBL] [Abstract][Full Text] [Related]
10. Laparoscopy for primary cytoreduction with multivisceral resections in advanced ovarian cancer: prospective validation. "The times they are a-changin"? Ceccaroni M; Roviglione G; Bruni F; Clarizia R; Ruffo G; Salgarello M; Peiretti M; Uccella S Surg Endosc; 2018 Apr; 32(4):2026-2037. PubMed ID: 29052073 [TBL] [Abstract][Full Text] [Related]
11. A study of clinicopathologic factors as indicators for early prediction of suboptimal debulking surgery after neoadjuvant chemotherapy in advanced ovarian cancer. Son JH; Chang K; Kong TW; Paek J; Chang SJ; Ryu HS J Obstet Gynaecol Res; 2018 Jul; 44(7):1294-1301. PubMed ID: 29683235 [TBL] [Abstract][Full Text] [Related]
12. Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy. Corrado G; Mancini E; Cutillo G; Baiocco E; Vici P; Sergi D; Patrizi L; Saltari M; Baffa A; Vizza E Int J Gynecol Cancer; 2015 Sep; 25(7):1253-7. PubMed ID: 26111273 [TBL] [Abstract][Full Text] [Related]
13. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy. Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP Oncology; 2015; 89(3):159-66. PubMed ID: 25968072 [TBL] [Abstract][Full Text] [Related]
14. Management of advanced ovarian cancer in South West Wales - a comparison between primary debulking surgery and primary chemotherapy treatment strategies in an unselected, consecutive patient cohort. Drews F; Bertelli G; Lutchman-Singh K Cancer Epidemiol; 2017 Aug; 49():85-91. PubMed ID: 28599137 [TBL] [Abstract][Full Text] [Related]
15. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study. Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976 [TBL] [Abstract][Full Text] [Related]
16. Survival outcomes after extensive cytoreductive surgery and selective neoadjuvant chemotherapy according to institutional criteria in bulky stage IIIC and IV epithelial ovarian cancer. Lim MC; Yoo HJ; Song YJ; Seo SS; Kang S; Kim SH; Yoo CW; Park SY J Gynecol Oncol; 2017 Jul; 28(4):e48. PubMed ID: 28541636 [TBL] [Abstract][Full Text] [Related]
17. Validation of the Integrated Prediction Model algorithm for outcome of cytoreduction in advanced ovarian cancer. Piedimonte S; Bernardini MQ; Ding A; Laframboise S; Ferguson SE; Bouchard-Fortier G; Avery L; May T; Hogen L Int J Gynecol Cancer; 2023 Jul; 33(7):1077-1082. PubMed ID: 37015756 [TBL] [Abstract][Full Text] [Related]
18. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy. Davidson BA; Broadwater G; Crim A; Boccacio R; Bixel K; Backes F; Previs RA; Salinaro J; Salani R; Moore K; Secord AA Gynecol Oncol; 2019 Mar; 152(3):554-559. PubMed ID: 30558972 [TBL] [Abstract][Full Text] [Related]
19. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy. May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250 [TBL] [Abstract][Full Text] [Related]